Endothelial Stem Cells Journals
Endothelial stem cells are one of three types of multipotent stem
cells found in bone marrow. They give rise to progenitor cells, which are intermediate stem
cells that lose potency, and eventually produce endothelial cells, which create the thin-walled endothelium that lines the inner surface of blood vessels and lymphatic vessels. The epithelial–mesenchymal transition (EMT) is a process by which epithelial
cells lose their cell polarity and cell–cell adhesion and gain migratory and invasive properties to become mesenchymal stem cells; these are multipotent stromal
cells that can differentiate into a variety of cell types. EMT is essential for numerous developmental processes, including mesoderm, neural tube formation, and wound healing. A growing body of evidence suggests that EMT plays a central role during
tumor metastasis and frequently imparts a stem cell-like
phenotype and therapeutic resistance to
tumor cells. The induction of EMT is accompanied by a dynamic reprogramming of the epigenome involving changes in DNA
methylation and several post-translational histone modifications . These changes in turn promote the expression of mesenchymal genes or repress those associated with an epithelial phenotype. EMT of
cancer cells is partly under reversible epigenetic control. Differences between cell types are guided by the expression of tissue-specific transcription factors and consolidation of associated epigenetic states. Therefore, the epigenome of a
cancer cell is determined in part by the cell of origin for that
cancer and includes passenger hypermethylation events at genes not required in that particular lineage . In order for metastatic colonization and the formation of macrometastases to occur,
tumor cells frequently undergo a reversal of EMT referred to as the mesenchymal-to-epithelial transition (MET). Thus, a high degree of epigenetic plasticity is required in order to induce and reverse EMT during
tumor progression.
High Impact List of Articles
-
Clinical trial transparency and the evaluation of new medicines
Bina Rawal and Bryan R Deane
Editorial: Clinical Investigation
-
Clinical trial transparency and the evaluation of new medicines
Bina Rawal and Bryan R Deane
Editorial: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 4
Acknowledgements: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials
Bamidele A Adesunloye, William L Dahut
Therapeutic Prospective: Clinical Investigation
-
Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials
Bamidele A Adesunloye, William L Dahut
Therapeutic Prospective: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth, Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth, Michael Thomas
Review Article: Clinical Investigation
Relevant Topics in Clinical